Table of Contents

• What is L-Arginine?
• L-Arginine in Cystic Fibrosis
• L-Arginine in Sickle Cell Disease
• L-Arginine in Lower Limb Ischemia
• L-Arginine in Presbyvestibulopathy
• L-Arginine in Muscular Dystrophy
• L-Arginine in Heart Transplant Patients
• L-Arginine in Kidney Injury
• L-Arginine in Rheumatoid Arthritis
• L-Arginine in MELAS Syndrome
• L-Arginine in Schizophrenia
• L-Arginine in Endothelial Dysfunction
• L-Arginine in High-Risk Pregnancy
• L-Arginine in Metabolic Syndrome
• L-Arginine in Critically Ill Patients
• L-Arginine in Hypertension
• L-Arginine and Brown Adipose Tissue
• L-Arginine in Thalassemia
• L-Arginine in Asthma
• L-Arginine in Polycystic Ovary Syndrome
• Dosage and Administration
• Potential Side Effects

What is L-Arginine?

L-arginine is a semi-essential or conditionally essential amino acid, depending on the developmental stage and health status of an individual. It’s classified as “semi-essential” because under normal conditions, the body can produce enough for its needs. However, during times of growth, trauma, or certain disease states, the body may require additional L-arginine from dietary sources or supplements ^[1].

L-arginine is a precursor for the synthesis of nitric oxide (NO), a molecule produced in the vascular endothelium with important physiological functions including vasodilation (widening of blood vessels), antiatherogenic (preventing plaque buildup in arteries), and antiplatelet (preventing blood clot formation) actions ^[11].

Research indicates that L-arginine plays a significant role in various bodily functions and has potential therapeutic applications across multiple medical conditions, particularly those involving vascular function, inflammation, and metabolic processes ^[17].

L-Arginine in Cystic Fibrosis

Cystic fibrosis (CF) is characterized by inflammatory lung disease, but interestingly, nitric oxide (NO) formation and expression of nitric oxide synthase 2 (NOS2) are found to be decreased in CF airways. This reduction in NO formation may contribute to lung pathophysiology in CF ^[1].

L-arginine, as the precursor of enzymatic NO formation, has been studied for its potential benefits in CF patients. Previous animal experiments have shown that adding L-arginine resulted in significantly greater relaxation of tracheas. Additionally, there is evidence that a single dose of inhaled L-arginine can improve pulmonary function in CF patients ^[1].

A clinical trial investigated the effect of inhaled L-arginine on lung function, NO formation, airway inflammation, and bacterial infection in CF patients. The study involved administering L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which patients took 2ml (500mg) and diluted with 3ml of sterile water to create a 100mg/ml solution. This was administered by inhalation using a PARI eFLOW device ^[1].

The primary outcomes measured were changes in FEV1 (Forced Expiratory Volume in 1 second) from baseline and monitoring adverse events such as gastrointestinal complaints, wheezing, hepatitis, or shortness of breath. Secondary outcomes included changes in FVC (Forced Vital Capacity), FEV25-75, exhaled nitric oxide (FeNO), and inflammatory markers in sputum ^[1].

L-Arginine in Sickle Cell Disease

Sickle Cell Disease (SCD) is associated with decreased bioavailability of nitric oxide and arginine. Multiple studies have investigated L-arginine supplementation in SCD patients to address this deficiency and potentially improve clinical outcomes ^[2][7].

One clinical trial aimed to evaluate the possible efficacy and safety of L-arginine in children with SCD who had increased Tricuspid Regurgitant Jet Velocity (TRJV), an indicator of pulmonary hypertension. The study included two groups: one receiving standard therapy for 3 months, and another receiving L-arginine 0.1-0.2 g/kg/day along with standard therapy for 3 months ^[2].

Another randomized, controlled trial studied the effects of L-arginine on pain management in SCD. This study investigated whether giving L-arginine to patients with SCD seeking treatment for a pain crisis (vaso-occlusive painful events) would decrease pain scores, reduce the need for pain medications, or decrease the length of hospital stay or emergency department visits ^[7].

The primary outcome measure in this study was the total amount of parenteral opioids used by participants measured in mg/kg of IV morphine equivalents. Secondary outcomes included the length of hospital stay, time to vaso-occlusive pain event resolution in the emergency department and hospital, change in pain scores, and rate of acute chest syndrome ^[7].

A Brazilian study provided L-arginine orally at a dose of 0.1g/kg/day for 6 months to SCD patients. This trial used tricuspid regurgitant jet velocity to assess pulmonary arterial hypertension before and after treatment, and also measured lactate dehydrogenase levels to evaluate the effect on hemolysis ^[20].

L-Arginine in Lower Limb Ischemia

For patients with severe lower limb ischemia requiring femoropopliteal bypass revascularization, L-arginine has been studied for its potential protective effects during reperfusion. The symptoms and severity of arterial disease are secondary to perfusion deficit, and specific alterations of mitochondrial function in ischemic skeletal muscle play an important role ^[3].

In severe ischemia, the necessary reperfusion can be accompanied by deleterious effects, including worsening of endothelial dysfunction (impaired pathway of nitric oxide), major alterations of cellular energy, and hormonal and inflammatory responses. This is known as reperfusion syndrome, which can have serious consequences ^[3].

A clinical trial investigated whether limiting mitochondrial and endothelial dysfunction (increased by reperfusion) by stimulating the NO pathway through in situ addition of L-arginine could provide benefits. The working hypothesis was that this cellular improvement would be accompanied by an increase in systolic pressure index and improved walking distance ^[3].

The study involved 30 patients receiving either 50, 100, or 500mg L-arginine supplementation infused via an end-hole catheter. The trial measured heart rate, blood pressure, and body temperature continuously. Gastrocnemius muscle biopsies were taken before and 30 minutes after revascularization to analyze mitochondrial respiration and its control. Both femoral and brachial concomitant venous samples were analyzed to assess muscle damage and released mediators ^[3].

L-Arginine in Presbyvestibulopathy

Presbyvestibulopathy is defined as a chronic vestibular syndrome characterized by bilateral vestibulopathy verified with vestibular tests. This condition is objectively assessed using tests like the video Head Impulse Test (v-HIT) and Vestibular Caloric Tests, as well as questionnaires such as the Dizziness Handicap Inventory for monitoring and prognosis ^[4].

Currently, there is no specific treatment for presbyvestibulopathy. A clinical trial was designed to evaluate the effect of L-arginine versus placebo on symptoms and changes in the results of vHIT tests in patients diagnosed with presbyvestibulopathy ^[4].

In this randomized, double-blind, placebo-controlled clinical trial, patients meeting the diagnostic criteria for Presbyvestibulopathy of the Barany Society were included. The experimental group received L-arginine at a dose of 3 grams divided into three doses of 1 g (capsules) every 8 hours, for 3 months. The control group received placebo at the same dosage. All patients also received vestibular rehabilitation exercises ^[4].

The primary outcomes measured were the Dizziness Handicap Inventory score and vHIT test results. Secondary outcomes included the “Up and Go” time test, which measures the time it takes for a patient to stand up from a chair without support, walk forward for 3 meters and back. This test is an indicator of fall risk, with durations greater than 10 seconds associated with increased risk ^[4].

The theoretical basis for using L-arginine in this condition is its vasodilator effect as a precursor of nitric oxide, which should favor vascular perfusion in the vestibular system ^[4].

L-Arginine in Muscular Dystrophy

Dystrophinopathy is a muscular dystrophy (including Duchenne or Becker’s Muscular Dystrophy) that can be a lethal muscle disorder resulting from defects in the gene for dystrophin, a structural protein required to maintain muscle integrity. The absence of functional dystrophin leaves the muscle membrane vulnerable to damage during contraction, which can be exacerbated by inflammatory responses leading to myofiber necrosis ^[5].

L-arginine has been postulated to affect dystrophinopathy in several favorable ways, including upregulation of utrophin, vasodilation in muscle via nitric oxide, enhanced synthesis of creatine, and increased levels of growth hormone ^[5].

A clinical study hypothesized that administration of L-arginine might increase levels of creatine and growth hormone, potentially reducing the extent of myofiber damage in patients with dystrophinopathy ^[5].

In this study, subjects received oral L-Arginine at a dose of 0.3 grams/kg/day, divided into 2 doses per day, not exceeding 14 grams/day. The primary outcome measure was MRI/MRS (Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy) of the calf muscle to assess muscle signal abnormalities and creatine levels before and after 30 days of L-arginine administration ^[5].

Secondary outcome measures included safety labs (complete blood count and comprehensive metabolic panel), assessment of muscle strength and function using a hand-held dynamometer, functional tests measuring time to walk specified distances and climb stairs, and pulmonary function tests to assess forced vital capacity ^[5].

L-Arginine in Heart Transplant Patients

A study investigating the effect of L-arginine in young heart transplant patients hypothesized that peripheral endothelial function and exercise tolerance would be abnormal in this population at baseline, and that each would show improvement following a 12-week course of oral L-arginine, with regression toward the baseline following a 12-week washout period ^[6].

The study subjects were treated with a 12-week course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (three 1000 mg capsules or caplets) ^[6].

The primary outcome measure was the change in peripheral endothelial function from baseline following the 12-week treatment course. Secondary outcomes included changes in serum levels of oxidative stress markers and exercise tolerance, assessed with a 6-minute walk test ^[6].

This study aimed to address the cardiovascular challenges faced by heart transplant recipients, particularly related to endothelial function and exercise capacity, through L-arginine supplementation ^[6].

L-Arginine in Kidney Injury

A clinical study investigated the association between early postoperative L-Arginine administration and acute kidney injury following cardiac surgery with cardiopulmonary bypass (CPB). The objective was to test if L-arginine could reduce the incidence of post-operative acute kidney injury (AKI) ^[8].

The study compared patients who received at least one dose of L-arginine in the early postoperative stage versus those who did not receive L-arginine. The primary outcome measure was the incidence of postoperative AKI, defined by Serum Creatinine Criteria (an absolute increase in serum creatinine of 0.3 mg/dL within 48 hours or a percentage increase of ≥50% within 7 days) or Urine Output Criteria (oliguria or anuria) ^[8].

Secondary outcomes included more severe AKI (KDIGO stage ≥ 2 or requiring dialysis), in-hospital mortality, and length of hospital stay ^[8].

Another study explored the role of decreased nitric oxide in the elevation of resting sympathetic nerve activity in chronic kidney disease (CKD) patients. The central hypothesis was that accumulation of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, constitutes a major mechanism for sympathetic overactivity and hypertension in patients with CKD ^[18].

This study aimed to determine if restoration of NO production with L-arginine infusion reduces sympathetic nerve activity (SNA) and blood pressure. Participants received an intravenous infusion of L-arginine (250-350 mg/kg) for 30 minutes, with continuous recording of muscle sympathetic nerve activity (MSNA), heart rate, and blood pressure ^[18].

L-Arginine in Rheumatoid Arthritis

A study was conducted to investigate the role of L-arginine supplementation in the treatment of DMARDs-refractory moderate to severe rheumatoid arthritis. The trial compared placebo to low dose L-arginine (9g per day, 3g three times daily) and high dose L-arginine (15g per day, 5g three times daily) ^[9].

The L-arginine was administered to the experimental groups for at least 24 weeks as an add-on treatment to the current Disease-Modifying Antirheumatic Drugs (DMARDs) treatments for rheumatoid arthritis ^[9].

The primary outcome measure was the response rate of ACR20 after 24 weeks of L-arginine administration. According to the American College of Rheumatology criteria, ACR20 is defined as both improvement of 20% in the number of tender and swollen joints, and a 20% improvement in three of five additional criteria (patient global assessment, physician global assessment, functional ability measure, visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein) ^[9].

Secondary outcomes included the response rates of ACR50/70 (similar instruments with improvement levels defined as 50% and 70% respectively), changes in DAS28/ESR (Disease Activity Score using 28 joint counts and Erythrocyte Sedimentation Rate), and monitoring for treatment-related adverse events ^[9].

L-Arginine in MELAS Syndrome

MELAS syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) is a condition where patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also experience unique ‘stroke-like’ episodes (SLEs) which are not due to blockages of large or medium arteries ^[10].

These ‘strokes’ are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision center. This leads to visual loss and paralysis ^[10].

A study investigated the efficacy of L-arginine therapy on endothelium-dependent vasodilation and mitochondrial metabolism in MELAS syndrome. The dietary amino acid L-arginine is known to dilate blood vessels, increasing blood flow, and to decrease toxic free radicals generated by dysfunctional mitochondria ^[10].

The study examined the effect of a single dose and a 6-week trial of oral L-arginine on brain blood vessel reactivity, brain cell activation, and muscle aerobic function to evaluate its potential in treating MELAS and other mitochondrial disorders that present with strokes ^[10].

The primary outcome measure was muscle function investigation via 31P-Magnetic resonance spectroscopy, studying exercising quadriceps using an MR-compatible up-down ergometer and an established aerobic exercise protocol. Secondary outcomes included total body maximal aerobic capacity, cerebrovascular reactivity via functional MRI-Blood oxygen level dependent (BOLD) imaging of the brain, and exhaled nitric oxide measurements ^[10].

L-Arginine in Schizophrenia

A randomized, double-blind, cross-over, placebo-controlled study investigated the addition of L-arginine to treatment as usual (TAU) in schizophrenia to determine if it further improves and enhances therapeutic efficacy (positive, negative, and depressive symptoms) and effectiveness of antipsychotic treatment ^[11].

The study was based on the understanding that glutamate N-methyl-D-aspartate (NMDA) receptors have functional connections to the nitric oxide (NO) system in the brain. Dysfunction of connectivity between the neuroregulators glutamate and NO has been implicated in mechanisms of psychosis. Therefore, any downstream effects of NMDA dysfunction in schizophrenia may be ultimately mediated by the NO system at a cellular level ^[11].

The trial involved patients diagnosed with schizophrenia or schizoaffective disorder who were randomized to receive L-arginine first/placebo second or placebo first/L-arginine second (cross-over design) in addition to their usual treatment. The active treatment period was 3 weeks, with a washout period of 5 days before switching to the alternative arm ^[11].

L-arginine was administered orally at a dose of 3 grams twice daily (total 6 grams per day). The primary outcome measure was the change from baseline in mean Positive and Negative Syndrome Scale (PANSS) total and subscale scores at 3 weeks. Secondary outcomes included changes in the Clinical Global Impression (CGI) scale and the Calgary Depression Scale for Schizophrenia (CDSS) ^[11].

L-Arginine in Endothelial Dysfunction

Endothelial dysfunction refers to impaired functioning of the endothelium, the thin layer of cells that lines the interior surface of blood vessels. L-arginine has been studied for its potential to improve endothelial function in various conditions ^[12].

One study assessed the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography. Thirty patients received either 50, 100, or 500mg L-arginine supplementation infused via an end-hole catheter ^[12].

The primary outcome measure was intravascular ultrasound (IVUS) mediated assessment of endothelial-dependent (EDR) and endothelial-independent (EIR) vasorelaxation before and after catheter-directed L-arginine delivery in patent arteries. Secondary outcomes included local arterial factors such as peripheral L-arginine and nitrotyrosine levels via mass spectrometry and morphologic parameters of plaque composition ^[12].

Another study investigated L-arginine metabolism in essential hypertension, hypothesizing that impaired endothelial function in essential hypertension is associated with alterations in L-arginine metabolism and transport. This study aimed to determine whether metabolism and transport of L-arginine are altered in patients with essential hypertension and whether these potential alterations can be targeted therapeutically ^[16].

L-Arginine in High-Risk Pregnancy

A clinical trial investigated the efficacy of the combination of acetylsalicylic acid (aspirin) and L-arginine to prevent preeclampsia in high-risk pregnant women. Preeclampsia is a major cause of maternal and perinatal morbidity and mortality, with an incidence ranging from 2 to 10% of pregnancies worldwide, and higher rates in developing countries ^[13].

Because preeclampsia is an idiopathic heterogeneous syndrome associated with endothelial damage, there is no fully effective treatment to decrease its morbidity and mortality. Therefore, prevention strategies are important. The use of aspirin alone has shown inconclusive results, and L-arginine has been observed to lower blood pressure in this population ^[13].

This double-blind, randomized, placebo-controlled trial compared two groups: one receiving acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 grams every 8 hours from the 20th week of pregnancy until delivery, and another receiving acetylsalicylic acid and placebo ^[13].

The primary outcomes measured were the incidence and severity of preeclampsia. Secondary outcomes included various maternal complications (pulmonary edema, acute myocardial infarction, acute respiratory distress syndrome, coagulopathy, renal failure, retinal damage, and mortality), intrauterine growth restriction, blood pressure measurements, pulse wave velocity, and adverse effects ^[13].

L-Arginine in Metabolic Syndrome

A double-blind, parallel study investigated whether long-term oral L-arginine administration could delay or prevent type 2 diabetes mellitus in patients with impaired glucose tolerance (IGT) and Metabolic Syndrome ^[14].

Metabolic Syndrome is characterized by a cluster of conditions including abdominal obesity, hypertriglyceridemia, low HDL cholesterol, and hypertension. Patients with Metabolic Syndrome are at increased risk of developing type 2 diabetes ^[14].

In this study, patients were randomly assigned to two arms: oral L-arginine (6.4 g/day, divided into morning and evening doses of 3.2 g) or placebo, in addition to diet and physical exercise. The treatment was maintained for 18 months, with visits every 3 months for clinical evaluation, blood samples, treatment supply, and collection of data on adverse events ^[14].

An oral glucose tolerance test (OGTT) was performed before entering the study and at the end of the study period. An additional OGTT was performed at an intermediate visit if fasting glucose levels were more than 126 mg/dl. A diabetic response caused the endpoint of the patient ^[14].

The primary outcome measure was to evaluate the efficacy of long-term L-Arginine therapy in preventing or delaying the clinical onset of type 2 diabetes mellitus. Secondary endpoints included defining if the treatment with L-arginine could improve insulin sensitivity and endothelial dysfunction, and identifying new risk profiles and candidate genes that characterize the subgroup of patients at higher risk of developing type 2 diabetes ^[14].

L-Arginine in Critically Ill Patients

A randomized, double-blind clinical trial investigated the concept of “directed immuno nutrition” by L-arginine for critically ill patients. The main objective was to demonstrate that the administration of L-arginine, based on a suspected deficit monitored by nasal nitric oxide measurement, could improve immune functions in critically ill patients at high risk of nosocomial infection ^[15].

Previous meta-analyses had demonstrated the beneficial effect of immuno nutrition in surgical patients, leading to a 50% reduction in the incidence of nosocomial infections. This beneficial effect seemed to be related to L-arginine content in the formula. However, in medical intensive care, such improvement had not been shown, possibly due to a more heterogeneous population ^[15].

The study hypothesized that this beneficial effect could be observed in selected patients of medical intensive care units. A decrease in exhaled and nasal NO has been demonstrated in critically ill patients, which may suggest an impairment of its production ^[15].

In this monocentric therapeutic trial, non-surgical patients admitted to a medical intensive care unit, under mechanical ventilation for an expected duration greater than 2 days, with decreased concentrations of nasal NO (less than 60 ppb), and without severe sepsis or septic shock, were enrolled. Patients were randomized to receive either a 5-day L-arginine treatment (200 mg/kg) or placebo ^[15].

The primary outcome measure was the expression of HLA-DR (a marker of immune function) in the L-arginine group compared to the placebo group. Secondary outcomes included additional immune markers, nosocomial infections in the first 15 days, and organ failure scores ^[15].

L-Arginine in Hypertension

Essential hypertension is characterized by impaired endothelial function. Data from normotensive subjects with a genetic predisposition to arterial hypertension suggest that endothelial dysfunction is a cause rather than a consequence of the condition ^[16].

In normotensive offspring of hypertensive parents, impaired endothelium-dependent vasodilation can be restored by supplementation of the nitric oxide precursor L-arginine, suggesting a defect in the L-arginine/NO pathway ^[16].

A study at the University of Erlangen-Nuremberg hypothesized that impaired endothelial function in essential hypertension is associated with alterations in L-arginine metabolism and transport. The research aimed to determine whether metabolism and transport of L-arginine are altered in patients with essential hypertension and whether these potential alterations can be targeted therapeutically ^[16].

The intervention involved oral administration of L-arginine for 4 weeks, with the primary outcome measure being the meaning of L-arginine transport and metabolism on endothelial function ^[16].

L-Arginine and Brown Adipose Tissue

A randomized placebo-controlled multicenter cross-over study investigated the effect of L-arginine on brown adipose tissue metabolism in South Asian and white Caucasian subjects ^[17].

Brown adipose tissue (BAT) is a type of fat that burns energy instead of storing it, playing a role in thermogenesis (heat production). The South Asian population faces an epidemic of type 2 diabetes, potentially linked to a disturbed energy metabolism ^[17].

Research discovered that Dutch South Asian subjects have 32% lower resting energy expenditure (REE) and 34% lower energy-combusting BAT compared to matched white Caucasians. Nitric oxide (NO) is crucial for BAT development, and South Asians have diminished NO bioavailability ^[17].

The study hypothesized that increasing NO generation in the body by administering L-arginine would improve the metabolic phenotype in South Asians by increasing BAT volume, thereby increasing REE and clearance of triglycerides and glucose by BAT ^[17].

In this study, mildly obese pre-diabetic male volunteers of South Asian and white Caucasian descent received L-arginine (9 gram/day) or placebo for 6 weeks, followed by a washout period of 4 weeks and then 6 weeks of the alternative treatment ^[17].

The primary outcomes measured were the standard uptake value of brown adipose tissue (assessed by cold-induced 18F-FDG PET-CT scan), energy expenditure (determined by indirect calorimetry), and fat mass (determined by DEXA scan). Secondary outcomes included body temperatures, skin perfusion, skeletal muscle mitochondrial respiration, brown adipocyte recruitment and inflammation in white adipose tissue, and various blood parameters ^[17].

L-Arginine in Thalassemia

A comparative clinical study evaluated the effect of L-arginine versus sildenafil in children with beta thalassemia associated with pulmonary hypertension ^[19].

Thalassemia is a genetic blood disorder characterized by abnormal hemoglobin production. Patients with thalassemia can develop pulmonary hypertension (high blood pressure in the arteries of the lungs), which can lead to right heart failure if left untreated ^[19].

The study compared two active treatment groups: one receiving L-arginine and another receiving sildenafil (a medication commonly used to treat pulmonary hypertension). The primary outcome measure was the number of patients showing improvement in pulmonary hypertension ^[19].

This research focused on exploring different treatment options for pulmonary hypertension in children with thalassemia, a serious complication that can significantly impact quality of life and long-term prognosis ^[19].

L-Arginine in Asthma

A clinical trial investigated the potential benefits of L-arginine in patients with severe asthma, grouped by exhaled nitric oxide levels. The study hypothesized that a subset of adult severe asthma patients would respond to supplemental L-arginine and derive clinical benefit from adding this therapy to standard-of-care asthma medications ^[21].

Specifically, the researchers hypothesized that patients with lower exhaled NO concentrations (less than 20 ppb) and lower nitric oxide synthase 2 (NOS2)/arginase I (Arg1) mRNA ratios in their airway epithelial cells would benefit more than “non-responders” ^[21].

The aim was to test whether adult severe asthma subjects with exhaled breath NO concentrations less than 20 ppb would have fewer American Thoracic Society (ATS)-defined asthma exacerbations over 3 months when treated with L-arginine compared to subjects with exhaled nitric oxide concentration (FeNO) greater than 25 ppb ^[21].

The study enrolled a total of 50 ATS-defined severe asthmatic subjects with ongoing asthma exacerbations in the past two months in a randomized, blinded, placebo-controlled, cross-over designed trial of L-arginine and placebo. The researchers compared 25 subjects with “low” FeNO less than 20 ppb with 25 subjects that had “high” FeNO greater than 25 ppb ^[21].

The primary outcome measure was the number of acute exacerbations at 3 months. A moderate asthma exacerbation was defined as any of the following: a drop in morning peak flow rate greater than 30% from baseline on 2 consecutive days, need for initiation of oral steroids or an increased dose of inhaled corticosteroids on any two consecutive days, or doubling of short-acting β-agonist use per day for 2 consecutive days ^[21].

The secondary outcome measure was the change in FEV1/FVC (Forced Expiratory Volume in one second/Forced Vital Capacity) ratio at 3 months, which is a standard measure of lung function ^[21].

L-Arginine in Polycystic Ovary Syndrome

A clinical study investigated the safety and efficacy of L-arginine in patients with Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder common among women of reproductive age, characterized by irregular menstrual cycles, excess androgen levels, and polycystic ovaries ^[22].

The study enrolled PCOS patients who met the trial criteria from the Shanghai 10th People’s Hospital. The intervention involved L-arginine therapy at a dose of 3 grams per day for three months ^[22].

The primary outcome measure was menstrual frequency (number of menstruations in a year). Secondary outcomes included various metabolic and hormonal parameters such as insulin resistance index, body mass index, fasting glucose and insulin levels, lipid profile (total cholesterol, triglycerides, HDL, and LDL), and hormone levels (total testosterone, free testosterone, sex hormone-binding globulin, androstenedione, and dehydroepiandrosterone) ^[22].

The researchers also analyzed changes in the gut microbiome before and after L-arginine treatment, aiming to clarify the effectiveness and safety of L-arginine treatment for PCOS ^[22].

Dosage and Administration

L-arginine dosages varied across different clinical trials and medical conditions. Here’s a summary of the dosages used in various studies:

• For cystic fibrosis: Inhaled L-arginine 500mg diluted to create a 100mg/ml solution, administered via inhalation device ^[1]
• For sickle cell disease: 0.1-0.2 g/kg/day orally ^[2] or intravenous infusion of 100-200 mg/kg ^[7]
• For lower limb ischemia: 50-500mg infused via catheter ^[3]
• For presbyvestibulopathy: 3 grams daily, divided into three doses of 1g every 8 hours ^[4]
• For muscular dystrophy: 0.3 grams/kg/day, divided into 2 doses per day, not exceeding 14 grams/day ^[5]
• For heart transplant patients: 6 grams per day, divided into morning and evening doses of 3g ^[6]
• For rheumatoid arthritis: 9-15 grams per day (3-5 grams three times daily) ^[9]
• For schizophrenia: 3 grams twice daily (total 6 grams per day) ^[11]
• For high-risk pregnancy: 3 grams every 8 hours from the 20th week of pregnancy until delivery ^[13]
• For metabolic syndrome: 6.4 grams per day, divided into morning and evening doses of 3.2g ^[14]
• For critically ill patients: 200 mg/kg for 5 days ^[15]
• For brown adipose tissue study: 9 grams per day in three doses (3g three times daily) ^[17]
• For polycystic ovary syndrome: 3 grams per day for three months ^[22]

Routes of administration included oral (tablets, capsules, or powder), inhalation, and intravenous infusion, depending on the condition being treated and the study design.

Potential Side Effects

While L-arginine is generally considered safe for most people when taken in appropriate doses, potential side effects have been reported in clinical studies. These may include:

• Gastrointestinal complaints (nausea, abdominal pain, diarrhea) ^[1]
• Wheezing or shortness of breath ^[1]
• Headache ^[9]
• Hypotension (low blood pressure) ^[13]

Most clinical trials included safety monitoring and assessment of adverse events. In many studies, L-arginine was well-tolerated, with few significant adverse effects reported. However, individual responses may vary, and it’s important to consult with a healthcare provider before starting L-arginine supplementation, especially for those with existing medical conditions or those taking other medications.